256 related articles for article (PubMed ID: 27864119)
1. Role of miR-139 as a surrogate marker for tumor aggression in breast cancer.
Dai H; Gallagher D; Schmitt S; Pessetto ZY; Fan F; Godwin AK; Tawfik O
Hum Pathol; 2017 Mar; 61():68-77. PubMed ID: 27864119
[TBL] [Abstract][Full Text] [Related]
2. MiR-4728-3p could act as a marker of HER2 status.
Li H; Zhou X; Zhu J; Cheng W; Zhu W; Shu Y; Liu P
Cancer Biomark; 2015; 15(6):807-14. PubMed ID: 26406406
[TBL] [Abstract][Full Text] [Related]
3. Effects of differential distribution of microvessel density, possibly regulated by miR-374a, on breast cancer prognosis.
Li JY; Zhang Y; Zhang WH; Jia S; Kang Y; Tian R
Asian Pac J Cancer Prev; 2013; 14(3):1715-20. PubMed ID: 23679262
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.
Gwak JM; Kim HJ; Kim EJ; Chung YR; Yun S; Seo AN; Lee HJ; Park SY
Breast Cancer Res Treat; 2014 Aug; 147(1):39-49. PubMed ID: 25086633
[TBL] [Abstract][Full Text] [Related]
5. MiR-128 regulation of glucose metabolism and cell proliferation in triple-negative breast cancer.
Xiao M; Lou C; Xiao H; Yang Y; Cai X; Li C; Jia S; Huang Y
Br J Surg; 2018 Jan; 105(1):75-85. PubMed ID: 29116653
[TBL] [Abstract][Full Text] [Related]
6. Abnormal expression of miR-1 in breast carcinoma as a potent prognostic factor.
Minemura H; Takagi K; Miki Y; Shibahara Y; Nakagawa S; Ebata A; Watanabe M; Ishida T; Sasano H; Suzuki T
Cancer Sci; 2015 Nov; 106(11):1642-50. PubMed ID: 26331797
[TBL] [Abstract][Full Text] [Related]
7. Decreased expression of MicroRNA-200 family in human breast cancer is associated with lymph node metastasis.
Xu F; He H; Huang W; Lin Y; Luo S; Du Q; Duan R
Clin Transl Oncol; 2016 Mar; 18(3):283-8. PubMed ID: 26201425
[TBL] [Abstract][Full Text] [Related]
8. MiR-155 expression level changes might be associated with initial phases of breast cancer pathogenesis and lymph-node metastasis.
Petrović N; Kolaković A; Stanković A; Lukić S; Řami A; Ivković M; Mandušić V
Cancer Biomark; 2016; 16(3):385-94. PubMed ID: 26889816
[TBL] [Abstract][Full Text] [Related]
9. Breast invasive ductal carcinoma diagnosis with a three-miRNA panel in serum.
Chen X; Li X; Wang J; Zhao L; Peng X; Zhang C; Liu K; Huang G; Lai Y
Biomark Med; 2021 Aug; 15(12):951-963. PubMed ID: 34293926
[No Abstract] [Full Text] [Related]
10. In bone metastasis miR-34a-5p absence inversely correlates with Met expression, while Met oncogene is unaffected by miR-34a-5p in non-metastatic and metastatic breast carcinomas.
Maroni P; Puglisi R; Mattia G; Carè A; Matteucci E; Bendinelli P; Desiderio MA
Carcinogenesis; 2017 May; 38(5):492-503. PubMed ID: 28334277
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer: Role of IGF-1 and IGFBP-3 expression in prognostication.
Raval A; Trivedi S
Indian J Exp Biol; 2016 Oct; 54(10):619-629. PubMed ID: 30084561
[TBL] [Abstract][Full Text] [Related]
12. Tumor-suppressive microRNA-34a inhibits breast cancer cell migration and invasion via targeting oncogenic TPD52.
Li G; Yao L; Zhang J; Li X; Dang S; Zeng K; Zhou Y; Gao F
Tumour Biol; 2016 Jun; 37(6):7481-91. PubMed ID: 26678891
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1.
Chen LL; Zhang ZJ; Yi ZB; Li JJ
Br J Cancer; 2017 Jun; 117(1):78-88. PubMed ID: 28571042
[TBL] [Abstract][Full Text] [Related]
14. Expression Analysis of miR-29b in Malignant and Benign Breast Tumors: A Promising Prognostic Biomarker for Invasive Ductal Carcinoma With a Possible Histotype-Related Expression Status.
Papachristopoulou G; Papadopoulos EI; Nonni A; Rassidakis GZ; Scorilas A
Clin Breast Cancer; 2018 Aug; 18(4):305-312.e3. PubMed ID: 29422258
[TBL] [Abstract][Full Text] [Related]
15. Ectopic expression of PLC-β2 in non-invasive breast tumor cells plays a protective role against malignant progression and is correlated with the deregulation of miR-146a.
Bertagnolo V; Grassilli S; Volinia S; Al-Qassab Y; Brugnoli F; Vezzali F; Lambertini E; Palomba M; Piubello Q; Orvieto E; Natali C; Piva R; Croce CM; Capitani S
Mol Carcinog; 2019 May; 58(5):708-721. PubMed ID: 30582225
[TBL] [Abstract][Full Text] [Related]
16. Decreased expression of microRNA-206 in breast cancer and its association with disease characteristics and patient survival.
Li Y; Hong F; Yu Z
J Int Med Res; 2013 Jun; 41(3):596-602. PubMed ID: 23696595
[TBL] [Abstract][Full Text] [Related]
17. HPK1 positive expression associated with longer overall survival in patients with estrogen receptor-positive invasive ductal carcinoma‑not otherwise specified.
Wang J; Song L; Yang S; Zhang W; Lu P; Li S; Li H; Wang L
Mol Med Rep; 2017 Oct; 16(4):4634-4642. PubMed ID: 28765906
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-132 is frequently down-regulated in ductal carcinoma in situ (DCIS) of breast and acts as a tumor suppressor by inhibiting cell proliferation.
Li S; Meng H; Zhou F; Zhai L; Zhang L; Gu F; Fan Y; Lang R; Fu L; Gu L; Qi L
Pathol Res Pract; 2013 Mar; 209(3):179-83. PubMed ID: 23399321
[TBL] [Abstract][Full Text] [Related]
19. Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.
Müller V; Gade S; Steinbach B; Loibl S; von Minckwitz G; Untch M; Schwedler K; Lübbe K; Schem C; Fasching PA; Mau C; Pantel K; Schwarzenbach H
Breast Cancer Res Treat; 2014 Aug; 147(1):61-8. PubMed ID: 25086636
[TBL] [Abstract][Full Text] [Related]
20. The microRNA-205-5p is correlated to metastatic potential of 21T series: A breast cancer progression model.
Stankevicins L; Barat A; Dessen P; Vassetzky Y; de Moura Gallo CV
PLoS One; 2017; 12(3):e0173756. PubMed ID: 28346474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
